Witness Testimony

Dr. Didier Raoult testified regarding his scientific perspective on COVID-19, beginning with his definition of a pandemic as an epidemic that spreads globally, while emphasizing that viral dynamics depend on mutation patterns and zoonotic reservoirs. He described SARS-CoV-2 as a highly mutagenic virus that produced multiple variants, some becoming globally dominant and others remaining regionally confined. He argued that viral epidemics historically exhaust themselves through accumulated mutations and that eradication of a zoonotic respiratory virus with multiple animal reservoirs is not feasible.
Raoult discussed his early advocacy of hydroxychloroquine based on prior intracellular research and its known pharmacological profile, stating that initial in vitro and observational findings suggested antiviral activity. He criticized large clinical trials and regulatory decisions, questioned the reliability of early PCR testing practices, and argued that COVID-19 mortality was heavily concentrated among elderly and high-risk populations. He maintained that vaccination did not prevent transmission and emphasized that vaccine policies should be evaluated strictly through benefit-risk analysis by age group, raising concerns about myocarditis, thrombotic events, and informed consent during emergency authorization.
Beyond clinical matters, Raoult addressed broader governance issues, including alleged censorship on social media and in scientific publishing, conflicts of interest within pharmaceutical regulation, and the ethical implications of compulsory vaccination under experimental conditions. He expressed concern about transparency in vaccine trial data, financial influence on global health institutions, and the role of administrative authorities in overriding medical judgment. He concluded that pandemic response should prioritize individualized medical care, transparent scientific evaluation, and democratic safeguards against institutional overreach.